Promising Strategy for Treatment of Lung Cancer

	Tweet

A research team at the Sahlgrenska Academy at the University of Gothenburg, Sweden, has shown in a study that two closely related enzymes could be targets for the treatment of lung cancer. The discovery was made when the researchers blocked the production of the two enzymes in transgenic mice. This resulted in inhibition of cell growth, fewer tumours and greater survival among the mice.

With many types of cancer, the growth and spread of tumours is stimulated by Ras and Rho proteins. For these proteins to function, they need to be modified by the closely related enzymes FT and GGT. A number of pharmaceutical companies have therefore developed substances that reduce the activity of these two enzymes with the aim of inhibiting the function of Ras and Rho proteins and so slowing the development of the disease.

However, treatment with various substances to block these two enzymes has often been non-specific, and their efficacy has varied widely.

This has made it difficult for researchers to assess the true potential of these enzymes as targets for medicines.

“We therefore developed genetic strategies in mice, known as transgenic mice, to switch off the genes coding for FT and GGT, enabling us to investigate whether a complete blockade of FT or GGT can inhibit the development of lung cancer, and whether this has side-effects in the lungs,” explains researcher Anna-Karin Sjögren, who led the study together with Meng Liu, both from the Department of Clinical and Molecular Medicine.

In their study, the researchers used transgenic mice which produce a mutated Ras protein that causes lung cancer. First, production of FT or GGT in these mice’s lungs was stopped by switching off the relevant genes.

“When we turned off the FT gene, the mice developed fewer lung tumours and lived longer,” says Meng Liu. “At cellular level, the blockade of FT meant that the tumour cells were no longer able to divide. When we blocked the production of GGT, we saw the same effects: inhibition of cell growth, fewer lung tumours and improved survival.”

In experiments where both genes were switched off at the same time, the number of lung tumours dropped sharply and the mice lived much longer. This means that the absence of these two enzymes does not have any obvious side-effects in the lungs, and that lung tumour cells seem to be more sensitive to the treatment than normal lung cells.

“Our findings show that FT and GGT are promising targets for the treatment of lung cancer,” the researchers explain. “The next step in our research is to find out whether blocking these enzymes can have side-effects in other tissues.”

---
Adapted from materials provided by University of Gothenburg, via EurekAlert!, a service of AAAS.

Reference:
M. Liu, A.-K. M. Sjogren, C. Karlsson, M. X. Ibrahim, K. M. E. Andersson, F. J. Olofsson, A. M. Wahlstrom, M. Dalin, H. Yu, Z. Chen, S. H. Yang, S. G. Young, M. O. Bergo. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proceedings of the National Academy of Sciences, 2010; DOI: 10.1073/pnas.0908396107

RELATED STORIES:
Advances in lung cancer research announced at conference   Family risk for lung cancer stronger in blacks   Early Diagnosis of Lung Cancer: Where Do We Stand?   Study reveals differences in cancer stage presentation between rural and urban patients   Lung cancer research concludes that early diagnosis as key for improving survival   Genetic variations raise lung cancer risk for smokers and ex-smokers   Elderly Dutch lung patients’ survival improved by new treatment options between 2003-2009   Red Wine May Lower Lung Cancer Risk   Lower survival rates of blacks with lung cancer may be explained by access to care   Genetic mutation associated with increased risk of lung cancer   Quick, easy test identifies aggressive type of lung cancer in never-smokers   Women Smokers, Higher Risk But Lower Death Rates from Lung Cancer   Roche’s Tarceva helps lung cancer patients   Micro-RNA determines malignancy of lung cancer   Daily drinking may raise risk of several cancers   New clinical trial for patients with asbestos-associated lung cancer   Vaccination with embryonic stem cells prevents lung cancer in mice   New lung cancer drug shows dramatic results for shrinking tumors   Ovary removal may raise risk of lung cancer   Study finds hospitals of last resort deliver lower quality of lung cancer care   CT screening can identify curable lung cancers   A new way to look at lung cancer and tobacco carcinogens

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]